Program
HS-20122
A development code. Also written as “HS-20122+Aumolertinib”, “HS-20122+Adbrelimab” and “HS-20122+Adbrelimab+Platinum-based Chemo”.
In Hansoh Pharmaceutical Group's pipeline, EGFR/c-MET bispecific ADC
. Its studies are mostly in Lung Neoplasms, led by Hansoh Pharmaceutical Group.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hansoh Pharmaceutical Group | 22 open or running | phase 1since Apr 7, 2025 | Apr 7, 2025 | Jan 31, 2028phase 1 · NCT06927570 |
- Named in Hansoh Pharmaceutical Group’s own pipeline as
HS-20122 (EGFR/c-MET bispecific ADC)
, phase 1, as of Aug 26, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 7, 2025First study: phase 1 study in Advanced Solid TumorsFirst studyNCT06927570 · 1,050 planned · China
- Jun 8, 2026Phase 1 study in Lung NeoplasmsNCT07645222 · 396 planned · China
Ahead
- Jan 31, 2028Primary completion: phase 1 study in Advanced Solid TumorsNCT06927570
- Oct 31, 2028Primary completion: phase 1 study in Lung NeoplasmsNCT07645222
TargetBeta
“EGFR/c-MET bispecific ADC”the company's pipeline, read by Claude · source
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| amivantamabrule | Johnson & Johnson | phase 3 | 16 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
| HS-20117 | Hansoh Pharmaceutical Group | phase 3 | 3 |
| pamvatamigrule | Betta Pharmaceuticals | phase 2 | 5 |
| TQB2922 | Sino Biopharmaceutical | phase 2 | 5 |
| TQB6411 | Sino Biopharmaceutical | phase 2 | 3 |
| Anti-EGFR/Anti-c-Met Bispecific Antibody-drug Conjugate VBC101rule | VelaVigo Cayman | phase 2 | 1 |
| Anti-c-Met/EGFR/VEGF Trispecific Antibody TAVO412rule | tavotek-biotherapeutics | phase 1 | 2 |
| Anti-EGFR/c-Met/c-Met-Topoisomerase-1 Inhibitor Trispecific Antibody-drug Conjugate BG-C0902rule | BeOne Medicines | phase 1 | 1 |
| Anti-EGFR/c-Met-CPT-113 Antibody-drug Conjugate JNJ-95437446 | Johnson & Johnson | phase 1 | 1 |
| HLX48 | Fosun Pharma | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07645222Lung Neoplasms · China | 1 | Recruiting | Oct 31, 2028 | 396 |
| NCT06927570Advanced Solid Tumors · China | 1 | Recruiting | Jan 31, 2028 | 1,050 |
How it is read
Names in the registry
- “HS-20122+Aumolertinib”, 1 entry
- “HS-20122+Adbrelimab”, 1 entry
- “HS-20122+Adbrelimab+Platinum-based Chemo”, 1 entry
- “HS-20122”, 1 entry
Codes read as this program: HS20122.
Conditions, from the studies’ own filings
- Lung Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.